公司资料
Galectin Therapeutics 股价、新闻与催化剂
- 股票代码:
- GALT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
3.71 USD (+0.82%)
收盘价
最后更新: 2026年9月17日
159M USD
市值
股价为何变动
截至 2026年9月17日，GALT 上涨 0.82%，收于 $3.71。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Galectin Therapeutics is a biotechnology company focused on fibrosis and metabolic-liver disease biology. Its story is centered on immune and fibrotic pathways in serious disease.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Galectin sits in specialty biotechnology.
商业模式特征
The company depends on clinical data, target validation, and the chance to build value in liver and fibrosis disease.
生物医药行业定位
Galectin is a catalyst-driven liver-disease name whose stock reacts strongly to development updates.
未来催化剂
- Galectin’s catalysts are belapectin and fibrosis / oncology updates, with any clinical step determining whether the program still has room. The company needs a stronger human signal to keep the story alive.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。